Di Pasquale et al., 2019, “Collagenase-assisted wound bed preparation: an in vitro comparison between Vibrio alginolyticus and Clostridium histolyticum collagenases on substrate specificity”, Int Wound J 2019
Study Type: in vitro study
Aim: to test through In vitro study why Vibrio alginolyticus collagenase preparation (Hyalo4 start – Fidia Farmaceutici) is not aggressive on perilesional, healthy skin as the commercial Clostridium histolyticum collagenase (Noruxol – Smith & Nephew).
Results:
The novel Vibrio alginolyticus collagenolytic enzyme is characterized by a single, highly purified 82-kDa end product for clinical use and it shows a better safety profile in pharmaceutical applications, with a considerably higher purity grade than any other commercially available collagenase from Clostridium histolyticum.
Vibrio alginolyticus collagenase acts specially on main target collagen, and doesn't affect other ECM proteins (decorin and fibronectin) like competitor.
Electrophoretic profile of Vibrio alginolyticus versus Clostridium histolyticum collagenase
Vibrio alginolyticus performs its lytic activity exclusively on necrotic tissue, sparing healthy tissue.
Vibrioalginolyticus collagenase loses 90% activity at pH 5.6, typical of normal healthy skin. In contrast, C. histolyticum collagenase preparation still retains 60% and 30% activity at pH values of 5.6 and 5.0, respectively, therefore implying that this enzyme pool is still able to degrade the ECM matrix in healthy At mild basic pH values (7.4-8.5), typical of chronic, non-healing wounds, both preparations are equally effective on the collagenic substrate.
